ReviewBMC medicine2021
Models of COVID-19 vaccine prioritisation: a systematic literature search and narrative review.
Review in BMC medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Reaching the margins: examining equity in Indonesia's COVID-19 vaccination strategy.BMJ global health · 2026Review
- Social inequalities in vaccine coverage and their effects on epidemic spreading.PLoS computational biology · 2025Article
- Biometric Strategies to Improve Vaccine Immunogenicity and Effectiveness.Biomimetics (Basel, Switzerland) · 2025Review
- Comparative evaluation of behavioral epidemic models using COVID-19 data.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Protect or prevent? A practicable framework for the dilemmas of COVID-19 vaccine prioritization.PloS one · 2025Article
- Learning from the COVID-19 pandemic: A systematic review of mathematical vaccine prioritization models.Infectious Disease Modelling · 2024Review
- BharatSim: An agent-based modelling framework for India.PLoS computational biology · 2024Article
- Optimization Modeling for Pandemic Vaccine Supply Chain Management: A Review and Future Research Opportunities.Naval research logistics · 2024Article
- Prioritising older individuals for COVID-19 booster vaccination leads to optimal public health outcomes in a range of socio-economic settings.PLoS computational biology · 2024Article
- Article
- Impact of the first year of COVID-19 vaccination strategy in Brazil: an ecological study.BMJ open · 2024Article
- Strategic Alliances in Global Health: Innovative Perspectives in the Era of Sustainable Development.Healthcare (Basel, Switzerland) · 2024Review
- Dietary Inulin to Improve SARS-CoV-2 Vaccine Response in Kidney Transplant Recipients: The RIVASTIM-Inulin Randomised Controlled Trial.Vaccines · 2024Article
- The impact of quality-adjusted life years on evaluating COVID-19 mitigation strategies: lessons from age-specific vaccination roll-out and variants of concern in Belgium (2020-2022).BMC public health · 2024Article
- Learning from the COVID-19 pandemic: a systematic review of mathematical vaccine prioritization models.medRxiv : the preprint server for health sciences · 2024Article
- Analysis of the yearly transition function in measles disease modeling.Statistics in medicine · 2024Article
- Mortality trends in people with disabilities before and during the COVID-19 pandemic in South Korea, 2017-2022.Frontiers in public health · 2024Article
- COVID-19 vaccination strategies in settings with limited rollout capacity: a mathematical modelling case study in Sierra Leone.BMC public health · 2023Article
- Long-term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: A modelling study.PLoS medicine · 2023Article
- Asymptotic Analysis of Optimal Vaccination Policies.Bulletin of mathematical biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundHow best to prioritise COVID-19 vaccination within and between countries has been a public health and an ethical challenge for decision-makers globally. We reviewed epidemiological and economic modelling evidence on population priority groups to minimise COVID-19 mortality, transmission, and morbidity outcomes.
methodsWe searched the National Institute of Health iSearch COVID-19 Portfolio (a database of peer-reviewed and pre-print articles), Econlit, the Centre for Economic Policy Research, and the National Bureau of Economic Research for mathematical modelling studies evaluating the impact of prioritising COVID-19 vaccination to population target groups. The first search was conducted on March 3, 2021, and an updated search on the LMIC literature was conducted from March 3, 2021, to September 24, 2021. We narratively synthesised the main study conclusions on prioritisation and the conditions under which the conclusions changed.
resultsThe initial search identified 1820 studies and 36 studies met the inclusion criteria. The updated search on LMIC literature identified 7 more studies. 43 studies in total were narratively synthesised. 74% of studies described outcomes in high-income countries (single and multi-country). We found that for countries seeking to minimise deaths, prioritising vaccination of senior adults was the optimal strategy and for countries seeking to minimise cases the young were prioritised. There were several exceptions to the main conclusion, notably that reductions in deaths could be increased if groups at high risk of both transmission and death could be further identified. Findings were also sensitive to the level of vaccine coverage.
conclusionThe evidence supports WHO SAGE recommendations on COVID-19 vaccine prioritisation. There is, however, an evidence gap on optimal prioritisation for low- and middle-income countries, studies that included an economic evaluation, and studies that explore prioritisation strategies if the aim is to reduce overall health burden including morbidity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.